共 28 条
[1]
Pallin DJ(2008)Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus Ann Emerg Med 51 292-298
[2]
Egan DJ(2014)Staphylococcus aureus bacteremia at five U.S. Academic Medical Centers, 2008–2011: significant geographic variation in community-onset infections Clin Infect Dis 59 798-807
[3]
Pelletier AJ(2011)Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children Clin Infect Dis 357 380-390
[4]
David MZ(2007)Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus N Engl J Med 59 1849-1855
[5]
Daum RS(2015)Extended-duration dosing and distribution of dalbavancin into bone and articular tissue Antimicrob Agents Chemother 41 1407-1415
[6]
Bayer AS(2005)Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections Clin Infect Dis 37 1298-1303
[7]
Liu C(2003)Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections Clin Infect Dis 370 2169-2178
[8]
Bayer A(2014)Once-weekly dalbavancin versus daily conventional therapy for skin infection N Engl J Med 40 374-380
[9]
Cosgrove SE(2005)Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens Clin Infect Dis 38 437-453
[10]
Daum RS(2015)Epidemiology of adverse drug reactions in Europe: a review of recent observational studies Drug Saf undefined undefined-undefined